Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (BEIGF) Other Non-Current Assets (2016 - 2025)

BeOne Medicines (BEIGF) has disclosed Other Non-Current Assets for 11 consecutive years, with $102.4 million as the latest value for Q4 2025.

  • Quarterly Other Non-Current Assets fell 36.18% to $102.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $102.4 million through Dec 2025, down 36.18% year-over-year, with the annual reading at $102.4 million for FY2025, 36.18% down from the prior year.
  • Other Non-Current Assets for Q4 2025 was $102.4 million at BeOne Medicines, down from $136.2 million in the prior quarter.
  • The five-year high for Other Non-Current Assets was $201.2 million in Q3 2024, with the low at $3.9 million in Q2 2022.
  • Average Other Non-Current Assets over 5 years is $93.0 million, with a median of $113.9 million recorded in 2023.
  • The sharpest move saw Other Non-Current Assets plummeted 90.36% in 2023, then surged 3785.61% in 2024.
  • Over 5 years, Other Non-Current Assets stood at $7.2 million in 2021, then soared by 942.0% to $75.1 million in 2022, then surged by 66.89% to $125.4 million in 2023, then grew by 28.02% to $160.5 million in 2024, then tumbled by 36.18% to $102.4 million in 2025.
  • According to Business Quant data, Other Non-Current Assets over the past three periods came in at $102.4 million, $136.2 million, and $161.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.